克罗恩病或溃疡性结肠炎治疗药物的超说明书处方
该研究基于荷兰所有大学医院IBD患者的前瞻性数据库,评估超说明书处方的比例与特征。4583例IBD患者共12651条药物记录中,19%为超说明书处方,32%患者曾暴露于超说明书药物。超说明书处方在溃疡性结肠炎中较克罗恩病更常见(37% vs 29%,P<0.001),吸烟者与使用≥5种药物者更易暴露。
要点
- IBD患者中32%曾暴露于超说明书药物,19%的药物记录为超说明书处方。
- 溃疡性结肠炎超说明书暴露率高于克罗恩病(37% vs 29%,P<0.001)。
- 吸烟者与使用≥5种药物者超说明书暴露率更高(均P<0.001)。
核心结论
- 约五分之一的IBD处方为超说明书处方,三分之一的IBD患者曾暴露于超说明书药物,尤其是溃疡性结肠炎患者。
研究设计与样本
- 研究使用荷兰所有大学医院IBD患者的前瞻性数据库,收集IBD药物处方与人口学数据;药物由药物评估委员会判定是否获批用于克罗恩病和/或溃疡性结肠炎;采用单变量和多变量分析识别预测超说明书使用增加的患者特征。
- 共纳入4583例IBD患者,数据库中有12651条历史与当前药物记录。
主要发现
- 12651条药物记录中2374条(19%)为超说明书处方;4583例IBD患者中1477例(32%)曾暴露于超说明书药物。
- 常见超说明书IBD药物为巯嘌呤(18%)、倍氯米松(12%)、硫鸟嘌呤(4%)和别嘌醇(3%)。
- 非硫嘌呤/甲氨蝶呤类超说明书药物用于243例患者(6%),其中生物制剂或托法替布用于47例IBD患者(1%)。
- 超说明书处方在溃疡性结肠炎中较克罗恩病更常见(37% vs 29%,P<0.001)。
- 吸烟者与病程中使用≥5种药物者更可能暴露于超说明书药物(吸烟33% vs 27%,多种药物使用66% vs 22%,均P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Off-label prescribing is encountered across various fields of medicine and creates alternative treatment options, but is associated with unknown safety risks. The use of off-label drugs for the treatment of patients with inflammatory bowel diseases (IBD) has not been characterised before. AIM: To assess the proportion and characteristics of off-label prescribing for IBD in tertiary care centres in the Netherlands. METHODS: A prospective database of IBD patients from all Dutch university hospitals was used to collect data on drug prescriptions for IBD and demographics. Drugs were classified as off-label if they were unlicensed for Crohn's disease and/or ulcerative colitis by the Medicines Evaluation Board. Uni- and multivariable analyses were used to identify patient-specific characteristics predictive of increased off-label use. RESULTS: For the induction and/or maintenance treatment of 4583 IBD patients, 12 651 historical and current drug records were available in the database. Of these, 2374 (19%) were considered off-label prescriptions. Out of 4583 IBD patients, 1477 (32%) were exposed to off-label drugs. Commonly prescribed off-label IBD drugs were mercaptopurine (18%), beclomethasone (12%), thioguanine (4%) and allopurinol (3%). Non-thiopurine/methotrexate off-label drugs were prescribed in 243 patients (6%), including biological agents or tofacitinib in 47 IBD patients (1%). Off-label prescriptions were more common in ulcerative colitis than Crohn's disease (37% vs 29%, P < 0.001). Smokers and patients that received ≥5 drug types during their disease course were more likely to be exposed to off-label drugs (smoking 33% vs 27% and multiple drug use 66% vs 22%, both P < 0.001). CONCLUSION: About one-fifth of prescriptions for IBD were off-label and one-third of IBD patients, especially ulcerative colitis patients, were exposed to off-label drugs.
引用
- Simsek M, Lissenberg-Witte BI, van Riswijk MLM, et al. Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2019. PMID: 30908719. doi:10.1111/apt.15229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。